PharmExec

Seamless Therapeutics Enters $1.12 Billion Global Research Collaboration with Eli Lilly to Develop Therapeutics for Hearing Loss

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss

Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...
GEN - Genetic Engineering and Biotechnology News

Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration

Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases ...
PharmExec

Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a ...